| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 1990 | 2016 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 513 | 2017 |
| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 306 | 2019 |
| DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer N Luo, MJ Nixon, PI Gonzalez-Ericsson, V Sanchez, SR Opalenik, H Li, ... Nature communications 9 (1), 248, 2018 | 198 | 2018 |
| Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ... JCI insight 3 (24), 2018 | 139 | 2018 |
| Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ... Science translational medicine 9 (402), eaai7993, 2017 | 121 | 2017 |
| Treatment-induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO1 TA Werfel, DL Elion, B Rahman, DJ Hicks, V Sanchez, ... Cancer research 79 (1), 171-182, 2019 | 68 | 2019 |
| Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta … M Hicks, ER Macrae, M Abdel-Rasoul, R Layman, S Friedman, J Querry, ... The oncologist 20 (4), 337-343, 2015 | 60 | 2015 |
| Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer ML Axelrod, MJ Nixon, PI Gonzalez-Ericsson, RE Bergman, MA Pilkinton, ... Clinical Cancer Research 26 (21), 5668-5681, 2020 | 49 | 2020 |
| Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers … DR Sudhan, LJ Schwarz, A Guerrero-Zotano, L Formisano, MJ Nixon, ... Clinical Cancer Research 25 (2), 771-783, 2019 | 40 | 2019 |
| PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer MJ Nixon, L Formisano, IA Mayer, MV Estrada, PI González-Ericsson, ... NPJ Breast Cancer 5 (1), 31, 2019 | 31 | 2019 |
| Pharmacologically increasing Mdm2 inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells AM Carrillo, M Hicks, D Khabele, CM Eischen Molecular Cancer Research 13 (8), 1197-1205, 2015 | 30 | 2015 |
| Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic X Zhang, M Luo, SR Dastagir, M Nixon, A Khamhoung, A Schmidt, A Lee, ... Nature Communications 12 (1), 2637, 2021 | 29 | 2021 |
| JUNB promotes the survival of Flavopiridol treated human breast cancer cells M Hicks, Q Hu, E Macrae, J DeWille Biochemical and biophysical research communications 450 (1), 19-24, 2014 | 16 | 2014 |
| MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement. JM Balko, DB Johnson, DY Wang, P Ericsson-Gonzalez, M Nixon, ... Journal of Clinical Oncology 36 (5_suppl), 180-180, 2018 | 10 | 2018 |
| Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. 2018; 3 DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ... | 10 | 2018 |
| Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, VM Jansen, JA Bauer, A Hanker, P Gonzalez Ericsson, ... Cancer Research 78 (4_Supplement), GS6-05-GS6-05, 2018 | 9 | 2018 |
| Mitogen-activated protein kinase signaling controls basal and oncostatin M-mediated JUNB gene expression MJ Hicks, Q Hu, E Macrae, J DeWille Molecular and Cellular Biochemistry 403, 115-124, 2015 | 8 | 2015 |
| DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9 (1): 248 N Luo, MJ Nixon, PI Gonzalez-Ericsson, V Sanchez, SR Opalenik, H Li, ... | 6 | 2018 |
| Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer A Hanna, MJ Nixon, MV Estrada, V Sanchez, Q Sheng, SR Opalenik, ... Breast Cancer Research 24 (1), 51, 2022 | 4 | 2022 |
